768 related articles for article (PubMed ID: 17177581)
21. Once-daily atazanavir/ritonavir compared with twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 96-week efficacy and safety results of the CASTLE study.
Molina JM; Andrade-Villanueva J; Echevarria J; Chetchotisakd P; Corral J; David N; Moyle G; Mancini M; Percival L; Yang R; Wirtz V; Lataillade M; Absalon J; McGrath D;
J Acquir Immune Defic Syndr; 2010 Mar; 53(3):323-32. PubMed ID: 20032785
[TBL] [Abstract][Full Text] [Related]
22. Economics of switching to second-line antiretroviral therapy with lopinavir/ritonavir in Africa: estimates based on DART trial results and costs for Uganda and Kenya.
Simpson KN; Baran RW; Kirbach SE; Dietz B
Value Health; 2011 Dec; 14(8):1048-54. PubMed ID: 22152173
[TBL] [Abstract][Full Text] [Related]
23. [Insulin resistance in HIV-infected patients receiving long-term therapy with efavirenz, lopinavir/ritonavir and atazanavir].
Bernal E; Masiá M; Padilla S; Ramos JM; Martín-Hidalgo A; Gutiérrez F
Med Clin (Barc); 2007 Jul; 129(7):252-4. PubMed ID: 17683706
[TBL] [Abstract][Full Text] [Related]
24. Atazanavir/ritonavir versus lopinavir/ritonavir: equivalent or different efficacy profiles?
Hill A
AIDS; 2005 Nov; 19(17):2054-5. PubMed ID: 16260922
[No Abstract] [Full Text] [Related]
25. Safety and feasibility of treatment simplification to atazanavir/ritonavir + lamivudine in HIV-infected patients on stable treatment with two nucleos(t)ide reverse transcriptase inhibitors + atazanavir/ritonavir with virological suppression (Atazanavir and Lamivudine for treatment Simplification, AtLaS pilot study).
Di Giambenedetto S; Fabbiani M; Colafigli M; Ciccarelli N; Farina S; Sidella L; D'Avino A; Mondi A; Cingolani A; Tamburrini E; Murri R; Navarra P; Cauda R; De Luca A
J Antimicrob Chemother; 2013 Jun; 68(6):1364-72. PubMed ID: 23372058
[TBL] [Abstract][Full Text] [Related]
26. Comparative gender analysis of the efficacy and safety of atazanavir/ritonavir and lopinavir/ritonavir at 96 weeks in the CASTLE study.
Squires KE; Johnson M; Yang R; Uy J; Sheppard L; Absalon J; McGrath D
J Antimicrob Chemother; 2011 Feb; 66(2):363-70. PubMed ID: 21148235
[TBL] [Abstract][Full Text] [Related]
27. Treatment durability, effectiveness, and safety with atazanavir/ritonavir-based HAART regimen in treatment-naïve HIV-infected patients.
Tremblay C; Trottier B; Rachlis A; Baril JG; Loutfy M; Lalonde R; Sampalis JS; Boulerice F
HIV Clin Trials; 2011; 12(3):151-60. PubMed ID: 21684855
[TBL] [Abstract][Full Text] [Related]
28. Cost effectiveness of darunavir/ritonavir 600/100 mg bid in protease inhibitor-experienced, HIV-1-infected adults in Belgium, Italy, Sweden and the UK.
Moeremans K; Annemans L; Löthgren M; Allegri G; Wyffels V; Hemmet L; Caekelbergh K; Smets E
Pharmacoeconomics; 2010; 28 Suppl 1():107-28. PubMed ID: 21182347
[TBL] [Abstract][Full Text] [Related]
29. Efficacy and safety of atazanavir-based highly active antiretroviral therapy in patients with virologic suppression switched from a stable, boosted or unboosted protease inhibitor treatment regimen: the SWAN Study (AI424-097) 48-week results.
Gatell J; Salmon-Ceron D; Lazzarin A; Van Wijngaerden E; Antunes F; Leen C; Horban A; Wirtz V; Odeshoo L; Van den Dungen M; Gruber C; Ledesma E;
Clin Infect Dis; 2007 Jun; 44(11):1484-92. PubMed ID: 17479947
[TBL] [Abstract][Full Text] [Related]
30. The potential cost and benefits of raltegravir in simplified second-line therapy among HIV infected patients in Nigeria and South Africa.
Schneider K; Nwizu C; Kaplan R; Anderson J; Wilson DP; Emery S; Cooper DA; Boyd MA
PLoS One; 2013; 8(2):e54435. PubMed ID: 23457450
[TBL] [Abstract][Full Text] [Related]
31. Cost-effectiveness of first-line antiretroviral therapy for HIV-infected African children less than 3 years of age.
Ciaranello AL; Doherty K; Penazzato M; Lindsey JC; Harrison L; Kelly K; Walensky RP; Essajee S; Losina E; Muhe L; Wools-Kaloustian K; Ayaya S; Weinstein MC; Palumbo P; Freedberg KA
AIDS; 2015 Jun; 29(10):1247-59. PubMed ID: 25870982
[TBL] [Abstract][Full Text] [Related]
32. [Efficacy of atazanavir in treatment-naive patients].
Moreno S; Hernández B; Dronda F
Enferm Infecc Microbiol Clin; 2008 Dec; 26 Suppl 17():9-13. PubMed ID: 20116611
[TBL] [Abstract][Full Text] [Related]
33. Comparison of atazanavir with lopinavir/ritonavir in patients with prior protease inhibitor failure: a randomized multinational trial.
Cohen C; Nieto-Cisneros L; Zala C; Fessel WJ; Gonzalez-Garcia J; Gladysz A; McGovern R; Adler E; McLaren C;
Curr Med Res Opin; 2005 Oct; 21(10):1683-92. PubMed ID: 16238909
[TBL] [Abstract][Full Text] [Related]
34. [Pharmacoeconomic aspects of lopinavir/ritonavir monotherapy].
Escobar Rodríguez I; Esteban Alba C
Enferm Infecc Microbiol Clin; 2008 Dec; 26 Suppl 16():47-51. PubMed ID: 19572445
[TBL] [Abstract][Full Text] [Related]
35. Does a significant reduction in malaria risk make lopinavir/ritonavir-based ART cost-effective for children with HIV in co-endemic, low-resource settings?
Ahmed BS; Phelps BR; Reuben EB; Ferris RE
Trans R Soc Trop Med Hyg; 2014 Jan; 108(1):49-54. PubMed ID: 24300443
[TBL] [Abstract][Full Text] [Related]
36. The CASTLE study: atazanavir/r versus lopinavir/r in antiretroviral-naive patients.
Chetchotisakd P
Expert Rev Anti Infect Ther; 2009 Sep; 7(7):801-5. PubMed ID: 19735222
[TBL] [Abstract][Full Text] [Related]
37. Effect of baseline protease genotype and phenotype on HIV response to atazanavir/ritonavir in treatment-experienced patients.
Naeger LK; Struble KA
AIDS; 2006 Apr; 20(6):847-53. PubMed ID: 16549968
[TBL] [Abstract][Full Text] [Related]
38. Lipid-lowering efficacy and safety after switching to atazanavir-ritonavir-based highly active antiretroviral therapy in patients with human immunodeficiency virus.
Nguyen ST; Eaton SA; Bain AM; Rahman AP; Payne KD; Bedimo R; Herrington JD; Maclayton DO; Rodriguez-Barradas MC; Busti AJ
Pharmacotherapy; 2008 Mar; 28(3):323-30. PubMed ID: 18294112
[TBL] [Abstract][Full Text] [Related]
39. Efficacy and safety of ritonavir-boosted dual protease inhibitor therapy in antiretroviral-naive HIV-1-infected patients: the 2IP ANRS 127 study.
Landman R; Capitant C; Descamps D; Chazallon C; Peytavin G; Katlama C; Pialoux G; Bentata M; Brun-Vézinet F; Aboulker JP; Yéni P;
J Antimicrob Chemother; 2009 Jul; 64(1):118-25. PubMed ID: 19420019
[TBL] [Abstract][Full Text] [Related]
40. Impact of switching from lopinavir/ritonavir to boosted and un-boosted atazanavir on glucose metabolism: the ATAzanavir & GLUcose metabolism (ATAGLU) study.
d'Ettorre G; Ceccarelli G; Zaccarelli M; Ascoli-Bartoli T; Bianchi L; Bellelli V; De Girolamo G; Serafino S; Giustini N; Mastroianni CM; Vullo V
Int J STD AIDS; 2016 Jul; 27(8):638-43. PubMed ID: 26068963
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]